Backlog Backfire: FDA Sees Increase In Pending Generic Applications At Deadline
Executive Summary
The agency was expecting many pending generic drug submissions to be withdrawn because sponsors would not want to pay the one-time backlog fee, but instead saw a substantial increase near the end of FY 2012.